Paper Review Records
全部论文审稿周期
20 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期；保留 PDF/DOI/网页源链接
373
天
Trials in progress: CARMAN – study protocol of a randomized controlled, international, multicenter, open-label phase II trial evaluating early treatment intensification in patients with high-risk mantle cell lymphoma using CAR-T-cell treatment after an abbreviated induction therapy with rituximab and ibrutinib and 6 months ibrutinib maintenance as compared to standard of care induction and maintenance
作者
Marie-Kristin Tilch; Christian Schmidt; Marek Trneny; Eva Giné; Olivier Hermine; Anke Ohler; Stephanie Herold; Eva Hoster; Linmiao Jiang; Christiane Pott; Martin Dreyling; Georg Hess展开收起
作者单位
1. Department of Hematology and Medical Oncology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany; 2. Department of Internal Medicine III, University Hospital, Ludwig Maximilian University (LMU) Munich, LMU Medizin, Munich, Germany; 3. First Department of Internal Medicine -Hematology, First Faculty of Medicine, General University Hospital, Charles University, Prague, Czech Republic; 4. Department of Hematology, Hospital Clínic of Barcelona, IDIBAPS, Barcelona, Spain; 5. CEREMAST Necker Hospital, Paris, France; 6. Institute for Medical Information Processing, Biometry, and Epidemiology (IBE), LMU Medizin, LMU Munich, Munich, Germany; 7. Department of Internal Medicine II, University Hospital Schleswig-Holstein, Kiel, Germany展开收起
35
天
DECIDER-2: Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all- trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy
作者
Olga Grishina; Claudia Schmoor; Caroline Sellner; Björn Hackanson; Jan-Henrik Mikesch; Iordanis Deligiannis; Felicitas Thol; Martina Crysandt; Christian Junghanss; Volker Runde; Paul La Rosée; Lino Lars Teichmann; Haifa Kathrin Al-Ali; Tim Sauer; Ulrich Germing; Frank Griesinger; Stefan Lukic; Jürgen Krauter; Snjezana Janjetovic; Jan Koch; Peter Staib; Julian Topaly; Maike de Wit; Doris Maria Kraemer; Lorenz Oelschläger; Ulf Schnetzke; Oliver Schmah; Swen Wessendorf; Cyrus Khandanpour; Lukas Kündgen; Monika Schwalenberg; Michael Heuser; Arnold Ganser; Hartmut Döhner; Ralph Wäsch; Michael Lübbert展开收起
作者单位
1. Clinical Trials Unit, Medical Center – University of Freiburg, Faculty of Medicine - University of Freiburg, Freiburg, Germany; 2. Department of Hematology/Oncology, Comprehensive Cancer Center Augsburg as Part of the CCC-WERA Consortium, University Medical Center Augsburg, Augsburg, Germany; 3. Department of Medicine A, University Hospital Münster, Münster, Germany; 4. Internal Medicine I, Brothers Hospital Trier, Trier, Germany; 5. Department of Hematology, Hemostasis, Oncology, and Cell Therapy, Hannover Medical School, Hannover, Germany; 6. Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Faculty, University Hospital Aachen, Aachen, Germany; 7. Department of Internal Medicine, Clinic for Hematology, Stem Cell Therapy and Palliative Medicine, Rostock University Medical Center, Hemostasis, Rostock, Germany; 8. Department of Hematology, Oncology and Palliative Care, Wilhelm-Anton- Hospital, Goch, Germany; 9. Department for Internal Medicine II, Schwarzwald‐Baar Klinikum, Villingen-Schwenningen, Germany; 10. Department of Medicine III, University Hospital Bonn, Bonn, Germany; 11. Krukenberg Cancer Center Halle, Medical Faculty, Martin-Luther- University Halle-Wittenberg, Halle (Saale), Germany; 12. Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany; 13. Department of Hematology, Oncology, and Clinical Immunology, Heinrich- Heine University Düsseldorf, Düsseldorf, Germany; 14. Clinic for Hematology and Oncology, Pius-Hospital Oldenburg, University Medicine Oldenburg, Oldenburg, Germany; 15. Department of Hematology and Oncology, Augusta-Kranken-Anstalt, Academic Teaching Hospital of the Ruhr-University Bochum, Bochum, Germany; 16. Department of Hematology and Oncology, Municipal Hospital Braunschweig, Braunschweig, Germany; 17. Department of Hematology and Cell Therapy, Helios Klinikum Berlin- Buch, Berlin, Germany; 18. University Medical Center Mannheim (UMM), Mannheim, Germany; 19. Department of Hematology and Oncology, St Antonius Hospital Eschweiler, Eschweiler, Germany; 20. Department of Hematology and Oncology, CaritasKlinikum Saarbrücken, Saarbrücken, Germany; 21. Department of Internal Medicine, Hematology, Oncology and Palliative Medicine, Vivantes Klinikum Neukölln, Berlin, Germany; 22. St. Josefs-Hospital Hagen, Hagen, Germany; 23. Department of Hematology and Oncology, Schleswig-Holstein, University Medical Center, University Cancer Center Schleswig-Holstein, Lübeck, Germany; 24. Department of Hematology and Medical Oncology, Clinic for Internal Medicine II, Comprehensive Cancer Center Central Germany-Campus Jena, University Hospital Jena, Jena, Germany; 25. Section of Hematology and Oncology, Ortenau Medical Care Center, Ortenau Klinikum Lahr, Lahr, Germany; 26. Department of Hematology and Oncology, Klinikum Esslingen, Esslingen, Germany; 27. University Clinic for Internal Medicine – Oncology and Hematology, Oldenburg Medical Center, University of Oldenburg, Oldenburg, Germany; 28. Department of Hematology, Oncology, Infectious Diseases and Palliative Care, Municipal Hospital Karlsruhe, Karlsruhe, Germany; 29. Department of Hematology, Oncology and Palliative Care, Hospital Lüdenscheid, Lüdenscheid, Germany; 30. Department of Internal Medicine IV, University Hospital Halle (Saale), Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany; 31. Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany; 32. Department of Hematology, Oncology and Stem Cell Transplantation, Medical Center – University of Freiburg, Faculty of Medicine - University of Freiburg, Freiburg, Germany展开收起
Expert Matching · Case Demo
把投稿要求，转成可验证的期刊方案
说清专业、时限和作者背景，CrushSCI 结合真实审稿样本，给出拟题方向、期刊初筛与周期判断。
客户询问
我是环境工程专业，需要一篇 SCI，希望 3 个月内见刊。没有基金，也没有大牛挂名，可以投哪些期刊？
CrushSCI回复
可以。先按 90 天时限做可行性筛选，同步查找无基金、无知名作者挂靠的典型论文案例，作为选刊依据。重点核对研究质量与期刊 scope。
- 拟题建议
- 《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》
样本口径2026 年最近 5 篇有效论文样本
平均审稿62 天
中位数65 天